chapter
review
numer
factor
thatinflu
laboratori
test
util
larg
commun
hospit
tabl
assess
laboratori
test
util
usual
reli
data
compil
util
review
analysi
necess
appropri
effici
laboratori
test
concurr
andor
retrospect
basi
laboratori
util
studi
report
academ
medic
center
howev
often
common
find
larg
commun
hospit
set
major
differ
academ
center
commun
healthcar
system
usual
number
hospitalemploy
physician
versu
independ
physician
offic
practic
larg
commun
hospit
employ
physician
medic
staff
like
kaiser
permanent
henri
ford
hospit
other
gener
easier
assembl
group
specialist
conven
laboratori
util
committe
meet
physician
accustom
leav
practic
respons
go
hospitalori
committe
meet
middl
day
sinc
focu
committe
review
evidencebas
evalu
new
old
laboratori
test
rule
specif
diseas
attend
qualiti
particip
vari
depend
physician
commit
project
larg
commun
hospit
may
save
time
meet
homework
assign
beforehand
includ
peopl
need
read
think
bring
come
prepar
discuss
meet
product
one
author
flk
work
year
direct
clinic
laboratori
outreach
laboratori
larg
commun
hospit
william
beaumont
hospit
royal
oak
mi
past
year
six
hospit
counti
healthcar
system
memori
healthcar
system
hollywood
fl
coauthor
rca
review
sever
issu
list
tabl
earli
initi
health
mainten
organ
hmo
hospit
purchas
physician
practic
gener
time
hospit
difficult
time
manag
physician
practic
second
recent
phase
buy
contract
design
enhanc
physician
product
key
motiv
hospit
acquisit
physician
practic
abil
gain
market
share
inpati
admiss
outpati
servic
captur
referr
physician
employ
own
practic
carlin
et
al
document
shift
inpati
admiss
outpati
ct
scan
mri
procedur
three
larg
multispecialti
clinic
system
two
hospitalown
integr
deliveri
system
id
id
purchas
shift
referr
pattern
new
hospit
owner
also
true
laboratori
test
order
newli
acquir
physician
practic
usa
physician
independ
compar
male
femal
physician
physician
employ
hospit
compar
downsid
trend
find
hospit
charg
doctor
work
attribut
caus
higher
overal
cost
current
trend
drive
laboratori
test
new
hospitalbas
physician
hospit
central
laboratori
consequ
potenti
util
issu
hospitalist
model
inpati
care
one
rapidli
grow
form
medic
practic
usa
sinc
introduct
hospitalist
usa
increas
hospitalist
practic
hospit
greater
bed
averag
start
salari
greater
intern
medicin
famili
practic
physician
hospitalist
work
strictli
hospit
overse
care
complex
patient
goal
reduc
need
transfer
patient
one
physician
anoth
larg
commun
hospit
use
voluntari
hospitalist
system
primari
care
physician
choos
admit
hospitalist
servic
attend
patient
larg
commun
hospit
like
adopt
hospitalist
model
case
mix
complex
greater
nation
averag
medicar
diagnosi
rate
group
index
high
health
mainten
organ
market
share
result
lower
interest
model
hypothesi
hospitalist
model
lead
reduct
patient
length
stay
total
hospit
cost
demonstr
hospitalist
may
order
excess
diagnost
test
secondari
lack
previou
knowledg
patient
choos
wise
campaign
sponsor
american
board
intern
medicin
foundat
consum
report
specialti
societi
recommend
reduct
elimin
inappropri
use
radiolog
laboratori
therapeut
procedur
first
societi
provid
five
select
relat
laboratori
test
patholog
one
list
societi
hospit
medicin
recommend
reduc
use
repetit
common
laboratori
test
patient
clinic
stabl
qualiti
improv
project
focus
hospitalist
effort
made
educ
reduc
repetit
use
complet
blood
count
basic
metabol
panel
panel
often
embed
order
set
establish
specif
diseas
specif
physician
simplifi
computer
physician
order
entri
baselin
period
intervent
follow
intervent
period
intervent
result
reduct
two
panel
order
per
patient
day
associ
decreas
direct
cost
per
patient
annual
save
studi
illustr
small
segment
laboratori
test
order
physician
impact
expens
overutil
analog
underutil
laboratori
test
like
first
round
hospit
buy
physician
practic
start
earli
consolid
merger
hospit
recent
increas
horizont
vertic
consolid
horizont
consolid
involv
hospit
merg
hospit
suppli
similar
servic
geograph
proxim
merger
like
investig
antitrust
violat
vertic
consolid
involv
hospit
consolid
health
care
provid
entiti
hospit
merger
acquisit
announc
involv
hospit
sixtyperc
hospit
part
health
system
downsid
merger
increas
price
secondari
increas
market
share
strategi
suggest
avoid
market
disequilibrium
us
hospit
market
rate
highli
competit
german
market
competit
number
hospit
system
decreas
myth
associ
latest
hospit
merger
activ
first
myth
consolid
equival
integr
second
higher
qualiti
associ
size
rather
leadership
competit
evid
support
suggest
hospit
competit
market
tend
better
administr
manag
combin
hospit
merger
increas
hospitalemploy
physician
lead
increas
laboratori
test
volum
need
robust
util
manag
practic
clinic
laboratori
improv
amend
clia
went
effect
septemb
regul
categor
laboratori
procedur
base
test
complex
use
welldefin
criteria
waiv
moder
complex
highli
complex
providerperform
microscopi
regul
defin
univers
test
larg
commun
hospit
laboratori
directli
indirectli
respons
util
manag
varieti
cliatest
classifi
waiv
fda
list
present
found
wwwaccessdatafdagovscriptscdrhcfdocscfcliatestswaivedcfm
implement
pointofcar
test
poct
usual
involv
desir
decreas
total
turnaround
time
analyt
test
improv
patient
outcom
howev
decreas
turnaround
time
alway
equal
improv
patient
outcom
two
prospect
studi
analyz
effect
poct
istat
devic
abbott
abbott
park
il
length
stay
emerg
depart
control
period
central
laboratori
use
istat
cartridg
analyz
sodium
potassium
chlorid
urea
glucos
calcul
hemoglobin
use
neither
studi
reveal
chang
length
stay
clinic
outcom
emerg
depart
patient
although
show
decreas
time
requir
obtain
laboratori
result
six
test
cartridg
istat
use
blood
test
ratelimit
step
patient
length
stay
similar
studi
use
five
differ
test
cartridg
istat
inr
lactat
brain
natriuret
peptid
troponin
chemistri
hemoglobin
hematocrit
singer
et
al
report
reduc
turnaround
time
poct
compar
central
laboratori
translat
reduct
time
complet
iv
contrast
ct
length
stay
specif
patient
clear
whether
reloc
poct
test
patient
bedsid
increas
decreas
test
volum
test
central
laboratori
report
adult
newborn
intensivecar
unit
patient
indwel
arteri
line
blood
drawn
laboratori
studi
patient
without
arteri
line
blood
loss
may
great
enough
requir
transfus
certainli
util
manag
poct
program
requir
investig
determin
relationship
total
laboratori
turnaround
time
result
patient
outcom
hospit
cost
use
cost
effect
analys
least
differ
sourc
bodi
fluid
human
laboratori
specimen
examin
brightfield
phase
contrast
microscop
classifi
providerperform
microscopi
ppm
clia
separ
cm
licens
avail
site
perform
assay
includ
koh
prepar
pinworm
detect
fern
test
microscop
urinalysi
semen
analysi
presenc
sperm
motil
eosinophil
nasal
smear
wise
laboratori
poctadministr
committe
assist
initi
ppm
test
program
collabor
ppm
licens
holder
clinic
defin
program
like
fern
test
labor
deliveri
area
direct
staff
obgyn
physician
model
train
util
manag
direct
hospit
poct
administr
committe
order
audit
laboratori
test
util
year
year
essenti
understand
test
volum
actual
count
test
panel
bundl
count
one
test
test
panel
unbundl
test
panel
count
separ
evalu
total
inpati
test
volum
depart
clinic
patholog
william
beaumont
hospit
royal
oak
mi
determin
method
count
inpati
test
chang
tabl
chang
count
methodolog
made
imposs
compar
data
year
year
done
import
done
way
year
year
two
categori
cost
reduct
hard
cost
save
soft
cost
avoid
tangibl
hard
cost
save
often
achiev
bring
refer
laboratori
test
inhous
clinic
laboratori
elimin
refer
laboratori
test
altogeth
intang
soft
cost
avoid
includ
thing
decreas
cost
associ
introduct
new
laboratori
test
intent
decreas
cost
futur
also
occur
cost
lower
origin
expens
would
otherwis
requir
cost
avoid
exercis
undertaken
sinc
process
consum
overhead
overheard
cost
money
signific
process
improv
could
repres
signific
cost
avoid
organ
total
cost
includ
direct
indirect
cost
direct
cost
includ
personnel
time
prepar
perform
test
reagent
qualiti
control
profici
test
equip
depreci
indirect
cost
includ
report
cost
comput
hospit
overhead
increment
margin
cost
includ
variabl
direct
cost
indirect
cost
therefor
increment
cost
demonstr
would
cost
perform
one
laboratori
test
assum
equip
facil
alreadi
avail
neither
total
cost
analysi
increment
cost
analysi
includ
analysi
defect
rate
failur
achiev
establish
goal
like
turnaround
time
defin
intern
extern
failur
rate
intern
failur
cost
incur
test
center
consequ
defect
test
system
receiv
test
result
incur
extern
failur
cost
util
laboratori
test
incur
intern
extern
failur
cost
excess
time
spent
laboratori
gener
result
excess
insur
charg
patient
nursingphysician
time
evalu
result
illustr
cost
avoid
consid
present
potenti
enteroviru
mening
emerg
depart
children
adult
detect
enteroviru
cerebrospin
fluid
csf
may
exhibit
symptom
mening
includ
photophobia
stiff
neck
acousticophobia
sever
headach
vomit
confus
difficulti
concentr
seizur
sleepi
molecular
test
enteroviru
detect
alter
patient
length
stay
emerg
depart
patient
posit
enteroviru
csf
specimen
patient
discharg
home
care
viral
mening
resolv
tabl
patient
enteroviru
csf
need
hospit
rule
bacteri
sourc
mening
cultur
sensit
studi
tabl
romero
demonstr
cost
rang
hospit
relat
enteroviru
testingcar
infect
averag
length
stay
day
use
calcul
tabl
illustr
cost
avoid
patient
without
enterovir
detect
molecular
method
cost
per
unit
went
could
make
longer
longer
run
ident
product
gave
rise
theori
economi
scale
laboratori
achiev
economi
scale
lower
unit
cost
per
test
expand
volum
laboratori
test
analyz
earli
number
inpati
laboratori
test
william
beaumont
hospit
began
decreas
fill
gap
prepar
period
initi
outreach
program
beaumont
refer
laboratori
expand
laboratori
test
servic
nonpati
physician
offic
nurs
home
hospit
sever
year
later
beaumont
refer
laboratori
join
region
laboratori
network
hospitalbas
laboratori
outreach
program
michigan
joint
ventur
hospit
laboratori
accommod
wide
geograph
coverag
requir
third
parti
payer
particip
laboratori
independ
own
oper
central
network
administr
coordin
negoti
manag
care
contract
volum
brl
specimen
grew
half
total
volum
clinic
patholog
procedur
six
million
test
increas
volum
permit
expans
test
menu
laboratori
section
review
procedur
order
physician
nine
subspecialti
area
famili
practic
pediatr
intern
medicin
cardiolog
endocrinolog
gastroenterolog
nurs
home
obgyn
urolog
requisit
physician
procedur
per
requisit
proceduresphysician
calcul
nine
group
physician
famili
practic
physician
intern
medicin
order
greatest
number
total
procedur
well
proceduresphysician
urolog
order
least
two
categori
test
order
nine
group
count
seven
laboratori
section
nine
group
order
chemistri
test
categori
percent
vari
obgyn
intern
medicin
popular
individu
test
five
laboratori
section
chemistri
hematolog
immunolog
microbiolog
molecular
diagnost
calcul
averag
number
specif
test
order
per
physician
per
month
use
data
laboratori
section
could
prepar
increas
util
sixmemb
intern
medicin
group
beaumont
refer
laboratori
sale
forc
sign
new
client
type
deep
dive
specif
physician
specialti
order
pattern
invalu
resourc
manag
grow
outreach
busi
million
request
chemistri
hematolog
microbiolog
test
includ
physician
calgari
canada
order
test
fiscal
year
physician
divid
subspecialti
averag
yearli
cost
per
group
averag
yearli
cost
per
physician
group
calcul
famili
practic
intern
medicin
greatest
averag
yearli
cost
per
group
hematolog
nephrolog
highest
averag
yearli
cost
per
physician
per
group
secondari
util
expens
laboratori
test
costbas
approach
util
review
requir
calcul
averag
median
cost
test
usa
would
much
less
price
list
hospit
charg
master
synergist
relationship
growth
beaumont
refer
laboratori
test
mix
complex
laboratori
section
molecular
diagnost
laboratori
start
ct
ng
perform
urin
use
ligas
chain
reaction
pcr
request
two
assay
brl
client
tabl
increas
volum
two
assay
help
turn
molecular
diagnost
section
profit
center
year
annual
util
review
reveal
outreach
program
contribut
volum
hospit
hospit
b
multiplex
assay
use
primarili
urin
specimen
made
margin
per
assay
bill
time
base
averag
medicar
reimburs
costtest
except
low
ng
volum
hospit
b
investig
learn
hospit
b
chose
less
sensit
ng
cultur
assay
retain
laboratori
test
volum
encourag
hospit
administr
also
myth
exist
hospit
b
ng
would
surviv
transport
time
min
hospit
order
physician
hospit
b
prevail
request
molecular
detect
ng
hospit
b
follow
case
illustr
complex
problem
solv
util
manag
issu
larg
commun
hospit
new
technolog
defin
disrupt
innov
offer
new
paradigm
diagnost
tabl
seven
technolog
list
tabl
share
similar
issu
includ
clarif
best
applic
routin
clinic
use
pauciti
evidencebas
outcom
literatur
review
educ
practition
physician
user
clinic
inform
gener
softwar
convert
big
databas
method
gener
use
inform
refer
tabl
direct
attent
issu
seven
disrupt
innov
paradigm
shift
strategi
becom
incorpor
daili
clinic
practic
debat
appropri
util
diminish
next
section
devot
time
describ
impact
current
chang
microbiolog
mass
spectrometri
bacteri
identif
multiplex
molecular
panel
infecti
agent
detect
respiratori
viral
panel
gastric
pathogen
panel
futur
chang
microscopi
antibacteri
drug
sensit
tradit
laboratori
diagnosi
infecti
diseas
pathogen
reli
cultur
vitro
growth
caus
agent
cultur
growth
achiev
autom
andor
manual
biochem
test
perform
identifi
microbi
organ
methodolog
depend
skill
medic
technologist
perform
manual
task
requir
determin
bacteri
identif
id
approach
id
antimicrobi
suscept
test
ast
depend
test
singl
pathogen
time
regardless
cultur
growth
yield
multipl
signific
pathogen
although
autom
id
ast
system
run
multipl
isol
help
streamlin
workflow
maxim
throughput
basic
test
still
individu
perform
isol
analyz
anoth
limit
factor
cultur
base
detect
method
bacteria
grow
well
vitro
ad
potenti
miss
signific
organ
viral
cultur
timeconsum
cytopath
effect
cpe
must
observ
method
use
determin
viral
identif
develop
viral
antigen
base
test
direct
fluoresc
antigen
dfa
rapid
antigen
test
devic
directli
sampl
shorten
cultur
time
obtain
faster
diagnosi
howev
reliabl
perform
viral
antigen
base
test
highli
depend
qualiti
sampl
collect
less
sensit
viral
cultur
suboptim
specimen
could
lead
fals
neg
antigendfa
result
viral
cultur
antigen
base
test
truli
need
clinic
microbiologyvirolog
laboratori
sinc
molecular
method
becom
new
gold
standard
mani
routin
clinic
microbiologyvirolog
laboratori
capabl
perform
viral
cultur
lack
physic
space
expertis
interpret
cpe
technolog
advanc
tradit
agrarian
societi
laboratori
becom
industri
implement
ofautom
molecular
base
test
use
mass
spectrometri
laser
desorpt
flight
mani
advanc
revolution
microbiolog
test
perform
disrupt
tradit
clinic
microbiolog
workflow
process
set
howev
technolog
advanc
shorten
time
laboratori
diagnosi
ultim
maxim
impact
patient
care
physician
larg
commun
hospit
util
rapid
microbiolog
laboratori
servic
trend
clinic
microbiolog
develop
syndrom
panel
use
molecular
techniqu
exampl
posit
blood
cultur
panel
develop
reduc
time
start
appropri
antibiot
patient
blood
cultur
bottl
flag
posit
gram
stain
smear
prepar
determin
presenc
bacteria
potenti
yeast
patient
blood
sampl
organ
seen
call
made
patient
healthcar
provid
broadspectrum
antimicrobi
therapi
initi
confirm
microbiolog
id
result
caveat
clinician
must
make
best
educ
guess
determin
antibiot
treatment
use
clinic
microbiolog
laboratori
typic
publish
antibiogram
clinician
hospit
pharmacist
know
preval
suscept
resist
phenotyp
common
bacteria
isol
although
provid
good
start
use
refer
heavi
emphasi
antimicrobi
stewardship
tailor
therapi
soon
possibl
less
pressur
develop
antimicrobi
resist
mani
institut
develop
process
develop
formal
antibiot
stewardship
programscommitte
effort
improv
util
antimicrobi
treatment
molecular
method
develop
within
one
test
identifi
number
pathogen
posit
blood
cultur
sampl
method
decreas
amount
time
provid
definit
id
abbrevi
antimicrobi
resist
genet
profil
advandxbiomerieux
inc
util
pnafish
peptid
nucleic
situ
hybrid
detect
posit
fluoresc
signal
directli
posit
blood
cultur
gram
stain
smear
find
typic
result
gram
posit
cocci
cluster
gram
neg
rod
tabl
inform
use
decid
broadspectrum
therapi
focus
therapi
ultim
goal
ensur
pathogen
adequ
treat
pnafish
assay
offer
four
basic
assay
gram
posit
gram
posit
gram
neg
candida
complement
gram
stain
result
clinician
least
presumpt
genu
identif
addit
pnafish
probe
abil
separ
aureuscoagulaseneg
staphylococcu
meca
probe
identif
mrsa
use
pnafish
assay
requir
fluoresc
microscop
visual
result
number
studi
shown
clinic
benefit
pnafish
implement
part
blood
cultur
workup
confirmatori
cultur
growth
potenti
identifi
methicillin
resist
genotyp
exampl
aureu
full
antibiot
suscept
perform
antibiot
therapi
therefor
tailor
deescal
appropri
similar
pnafish
scenario
util
cepheid
xpert
mrsasa
blood
cultur
test
gram
stain
smear
prepar
posit
blood
cultur
smear
determin
whether
cepheid
assay
run
cepheid
methodolog
realtim
pcr
base
requir
subject
interpret
result
laboratori
staff
cartridg
xpert
mrsasa
test
hous
reagent
compartment
accommod
nucleic
acid
extract
pcr
amplif
detect
one
devic
test
autom
sampl
load
test
cartridg
softwar
analyz
pcr
amplif
curv
determin
patient
blood
sampl
posit
neg
mrsa
mssa
cepheid
advandx
test
must
ad
alreadi
exist
workflow
serv
anoth
laboratori
tool
quickli
determin
pathogen
identif
preliminari
ast
profil
nanospher
inc
biofir
diagnost
inc
approach
test
posit
blood
cultur
bottl
target
common
pathogen
bacteria
yeast
caus
sepsi
uniqu
approach
due
overlap
patient
symptom
specif
syndrom
condit
symptom
overlap
clinician
difficulti
defin
caus
pathogen
infect
patient
sole
clinic
pictur
delay
specif
pathogenbas
therapi
use
syndrom
multiplex
molecular
panel
streamlin
test
process
oneanddon
approach
nanospher
offer
differ
panel
gram
posit
bcgp
panel
gram
neg
bcgn
panel
yeast
bci
panel
organ
observ
gram
stain
smear
determin
panel
run
addit
test
gram
posit
gram
neg
panel
also
includ
test
certain
antibiot
resist
gene
encod
methicillin
meca
vancomycin
vana
vanb
resist
tabl
mani
studi
show
overal
good
perform
bcgp
panel
gram
neg
speci
candida
spp
panel
limit
molecular
test
observ
buchan
et
al
posit
meca
target
abl
assign
due
presenc
mix
infect
case
full
antibiot
sensit
test
still
recommend
tradit
method
test
bacteri
pathogen
individu
beal
et
al
note
blood
cultur
infect
caus
one
pathogen
good
perform
multiplex
molecular
assay
polymicrobi
blood
cultur
infect
note
agreement
routin
cultur
mesta
et
al
also
notic
lower
percentag
agreement
polymicrobi
infect
compar
monomicrobi
infect
polymicrobi
bacteremia
rel
rare
potenti
sever
cultur
still
requir
identifi
full
antibiot
suscept
profil
identifi
pathogen
includ
multiplex
molecular
panel
filmarray
blood
cultur
identif
panel
bcid
anoth
comprehens
panel
cover
gram
posit
gram
neg
yeast
pathogen
tabl
gram
stain
requir
howev
still
good
routin
practic
perform
gram
stain
correl
result
molecular
panel
result
eventu
cultur
test
antibiot
suscept
test
altum
et
al
observ
certain
pathogen
detect
routin
cultur
detect
filmarray
panel
pathogen
molecular
panel
although
comprehens
panel
cover
common
pathogen
clinic
intuit
still
ultim
need
especi
clinic
symptom
laboratori
data
point
bacterem
process
set
neg
filmarray
panel
overal
assay
show
potenti
decreas
tat
preliminari
suscept
profil
base
antibiot
resist
gene
test
abil
rapid
answer
technic
sensit
specif
posit
downstream
effect
patient
care
antibiot
stewardship
impact
rapid
pcr
blood
cultur
assay
clinic
end
user
infect
control
pharmaci
length
stay
overal
hospit
cost
well
defin
one
studi
bauer
et
al
demonstr
clinic
benefit
implement
cepheid
xpert
mrsasa
assay
posit
blood
cultur
prepcr
period
evalu
follow
postpcr
period
overal
shorter
length
stay
day
shorter
mean
hospit
cost
less
observ
prepcr
period
infecti
diseas
pharmacist
effect
deescal
chang
specif
antibiot
therapi
compar
prepcr
period
benefit
gain
rapid
sensit
test
adopt
newer
molecular
method
laboratori
must
work
clinic
counterpart
determin
clinic
util
rapid
test
cost
potenti
benefit
newer
test
may
warrant
clinic
staff
abl
effect
util
inform
workflow
even
though
downstream
benefit
document
almost
inargu
clinic
perspect
financi
workflow
impact
microbiologymolecular
laboratori
implement
assay
mention
prior
gram
stain
result
posit
blood
cultur
help
drive
cultur
workup
thu
time
requir
blood
cultur
bottl
alarm
posit
cultur
time
wait
growth
cultur
plate
use
molecular
method
must
introduc
workflow
add
addit
work
cultur
id
ast
method
still
must
perform
set
continu
decreas
incom
medic
technologist
graduat
increas
number
laboratorian
retir
put
burden
addit
test
exist
staff
anoth
exampl
clinic
benefici
disrupt
test
within
laboratori
develop
respiratori
pathogen
panel
molecular
multiplex
panel
develop
target
gener
syndrom
respiratori
ill
tabl
show
varieti
fdaapprov
assay
avail
vari
number
pathogen
offer
within
respect
multiplex
assay
assay
also
requir
vari
level
handsoninvolv
molecular
expertis
requir
medic
technologist
prior
implement
respiratori
viru
panel
rvp
institut
viral
test
offer
rapid
antigen
immunochromatograph
devic
influenza
ab
respiratori
syncyti
viru
rsv
addit
offer
rvp
test
abl
provid
clinician
comprehens
answer
viru
es
occur
patient
benefit
transplant
immunocompromis
oncolog
patient
frequent
respiratori
viral
infect
serendipit
brought
rvp
outbreak
demonstr
poor
perform
rapid
antigen
test
observ
mani
laboratori
discontinu
rapid
antigen
test
offer
offer
molecular
test
laboratori
observ
declin
rapid
influenza
rsa
antigen
test
fig
spike
volum
relat
influenza
outbreak
elimin
rapid
antigen
test
favor
rapid
molecular
test
influenza
rsv
algorithm
reflex
neg
rapid
molecular
influenza
ab
rsv
test
comprehens
viral
andor
bacteri
panel
compar
dfa
andor
shell
vial
cultur
molecular
multiplex
respiratori
viru
panel
save
time
lower
cost
patient
despit
clinic
benefit
observ
limit
molecular
base
methodolog
batch
take
hour
perform
laboratori
exampl
laboratori
test
time
h
compar
take
run
rapid
antigen
test
trade
time
result
offset
increas
sensit
specif
breadth
viral
pathogen
discov
challeng
clinician
mani
time
want
fast
answer
purpos
triag
take
action
patient
howev
question
ask
whether
want
bad
qualiti
rapid
answer
good
qualiti
notsofast
answer
biofir
diagnost
inc
attempt
solv
test
time
problem
offer
comprehens
respiratori
pathogen
panel
test
directli
respiratori
specimen
one
patient
run
one
instrument
assay
time
approxim
h
certain
institut
set
technolog
benefit
urgent
care
clinic
smaller
commun
hospit
within
laboratori
minim
molecular
test
experi
howev
institut
higher
volum
batch
test
optim
biofir
may
best
solut
commerci
panel
differ
number
pathogen
offer
well
variou
level
medic
technologist
involv
tabl
decis
implement
one
panel
driven
myriad
factor
cost
workflow
physician
demand
technic
capabl
laboratori
staff
whatev
respiratori
pathogen
panel
introduc
rememb
sampl
test
volum
highli
depend
season
variat
figur
show
graph
volum
two
respiratori
viru
season
august
april
peak
volum
occur
winter
month
variabl
signific
impact
microbiologymolecular
laboratori
staf
physician
demand
coupl
increas
test
volum
may
high
enough
warrant
increas
number
run
per
day
staf
level
allow
potenti
lead
increas
employe
overtim
hour
interestingli
respiratori
viru
season
amidst
report
influenza
vaccin
suboptim
efficaci
observ
larg
increas
rvp
test
volum
compar
prior
season
thu
one
factor
virtual
imposs
control
antigen
driftshift
influenza
viru
affect
effect
current
vaccin
use
assay
perform
may
also
affect
due
genet
mutat
introduc
pcr
target
gene
region
limit
cultur
antigen
base
test
coinfect
greatli
underappreci
respiratori
viral
infect
one
expect
increas
incid
coinfect
multiplex
molecular
panel
figur
show
experi
coinfect
among
pediatr
adult
patient
clinic
signific
coinfect
complet
understood
relationship
modul
diseas
sever
research
need
fulli
understand
coinfect
interact
pathogen
present
well
interact
everi
respiratori
viru
season
laboratori
publish
virogram
show
preval
virus
current
circul
among
patient
popul
fig
b
infecti
gastrointestin
ill
anoth
syndrom
target
commerci
vendor
write
number
fdaapprov
assay
luminex
inc
biofir
diagnost
inc
becton
dickinson
diagnost
inc
nanospher
inc
genprobeprodess
tabl
clinician
often
unawar
pathogen
actual
includ
order
stool
cultur
ova
parasit
p
test
similar
respiratori
ill
symptom
symptom
infecti
gastrointestin
gi
ill
overlap
also
make
difficult
ascertain
true
pathogen
caus
diseas
develop
infecti
gi
panel
target
bacteri
viral
parasit
pathogen
provid
effici
approach
diagnosi
compar
standard
practic
appeal
clinic
microbiolog
laboratori
consolid
cultur
antigen
biochem
singlemolecular
analyt
test
one
comprehens
panel
implic
state
public
health
laboratori
reli
cultur
isol
epidemiolog
type
character
may
immedi
recogn
consid
molecular
stool
panel
test
improv
abil
detect
pathogen
molecular
method
compar
cultur
scenario
molecular
test
posit
cultur
growth
neg
imper
clinic
laboratori
commun
statepubl
health
laboratori
counterpart
come
amen
solut
given
discord
molecular
cultur
result
isol
requir
sent
statepubl
health
laboratori
similar
respiratori
coinfect
gi
coinfect
also
underappreci
aspect
diseas
pathogen
potenti
make
gi
coinfect
confus
would
requir
addit
clinic
scrutini
bacteria
colon
ie
c
difficil
burden
determin
clinic
signific
left
clinician
malditof
anoth
technolog
shorten
time
result
determin
microbi
identif
clinic
signific
pathogen
reader
refer
number
refer
review
articl
technolog
recent
malditof
system
made
commerci
avail
use
clinic
microbiolog
laboratori
technolog
compar
current
avail
test
culturebiochem
dna
sequenc
outsid
scope
chapter
malditof
outperform
convent
method
overal
accuraci
time
result
laboratori
implement
malditof
identif
tool
result
avail
approxim
day
earlier
compar
tradit
cultur
base
test
branda
et
al
found
malditof
reduc
turnaround
time
day
compar
tradit
test
side
effect
observ
increas
number
call
clinician
ask
antimicrobi
suscept
result
result
avail
next
day
autom
ast
system
addit
laboratori
need
adapt
workflow
process
malditof
test
implement
upfront
cost
instrument
high
approxim
result
delay
implement
clinic
microbiolog
laboratori
financi
save
realiz
cost
per
isol
run
malditof
compar
cost
per
isol
tradit
workup
reduct
reagent
laboratori
cost
compar
culturebiochem
methodolog
despit
initi
capit
expenditur
obtain
instrument
costsav
malditof
implement
organ
malditof
databas
need
confirm
tradit
method
andor
dna
sequenc
anoth
potenti
limit
definit
speciat
malditof
confus
clinician
end
user
see
new
bacteri
genusspeci
name
readili
recogn
may
pose
challeng
decid
antibiot
prescrib
new
definit
identif
result
technolog
advanc
greater
abil
speciat
bacteria
genu
answer
may
given
tradit
techniqu
ie
coagulaseneg
complex
laboratori
perspect
chang
nomenclatur
must
updat
laboratori
inform
system
appropri
microorgan
undergo
taxonom
reclassif
futur
advanc
malditof
technolog
also
affect
clinic
microbiolog
laboratori
workflow
studi
preliminarili
shown
abil
detect
pathogen
directli
patient
sampl
ie
posit
blood
cultur
urin
bypass
current
requir
test
cultur
isol
howev
stress
direct
sampl
test
earli
stage
develop
antibiot
suscept
test
also
examin
hrabak
et
al
provid
indepth
review
use
malditof
purpos
interestingli
technolog
also
describ
identifi
speci
tick
potenti
minim
ectoparasit
experi
normal
requir
technolog
advanc
focus
shorten
time
pathogen
detect
clinic
action
taken
much
quickli
two
rel
new
compani
work
methodolog
disrupt
clinic
microbiolog
practic
biosystem
inc
recent
receiv
fda
approv
detect
five
speci
c
albican
c
tropicali
c
parapsilosi
c
krusei
c
glaboratoryrata
direct
patient
blood
sampl
without
prior
incub
within
blood
cultur
bottl
biosystem
assay
claim
detect
candida
speci
within
h
technolog
shorten
start
time
appropri
candidemia
treatment
patient
mortal
decreas
earlier
treatment
start
abil
identifi
particular
candida
speci
critic
sinc
signific
rate
azol
resist
similar
blood
cultur
test
mention
technolog
elimin
need
culturepcr
antimicrobi
suscept
test
blood
cultur
bottl
becom
posit
technolog
allow
process
whole
blood
sampl
sinc
thermost
mutat
dna
polymeras
affect
inhibitor
whole
blood
detect
use
amplifi
dna
detect
pcr
product
done
via
magnet
reson
technolog
clinic
trial
data
show
overal
sensit
mean
time
h
detect
speci
identif
limit
detect
cfuml
know
patient
blood
sampl
posit
import
know
sampl
neg
candida
assay
observ
neg
predict
valu
studi
demonstr
earlier
detect
effect
antimicrobi
stewardship
rel
new
technolog
hospit
healthcar
institut
current
determin
optim
cost
effect
way
util
technolog
test
intend
screen
tool
use
target
patient
popul
candidemia
signific
like
occur
acceler
diagnost
inc
develop
methodolog
rapid
pathogen
identif
antimicrobi
suscept
test
purportedli
perform
within
h
wwwaccerlatediagnosticscom
compani
conduct
clinic
trial
blood
cultur
pathogen
panel
time
write
technolog
util
fish
dna
probe
identifi
panel
pathogen
may
present
antimicrobi
suscept
test
result
determin
singlecel
microbiolog
analysi
via
timelaps
computer
imag
pathogen
growth
characterist
presenc
particular
antibiot
blood
cultur
pathogen
panel
assay
intend
compani
first
fdaapprov
assay
sampl
type
panel
assay
pipelin
autom
microbiolog
laboratori
slow
make
impact
unlik
laboratori
section
ie
chemistri
urinalysi
etc
attribut
inher
manual
process
specimen
prepar
requir
vendor
develop
autom
plate
streaker
consist
yield
cultur
plate
also
compani
develop
autom
specimen
processor
program
inocul
batteri
plate
one
imagin
advantag
gain
high
volum
section
laboratori
urin
cultur
implement
microbiolog
autom
infanc
debat
util
autom
widespread
adopt
potenti
larg
impact
manual
workflow
disrupt
clinic
microbiolog
laboratori
function
obvious
financi
aspect
implement
autom
estim
total
cost
total
autom
microbiolog
solut
million
dollar
realm
possibl
advanc
total
microbiolog
laboratori
autom
technolog
solut
clinic
microbiologist
may
abl
function
virtual
bench
abl
work
cultur
setup
downstream
test
comput
touchscreentablet
elimin
potenti
hazard
expos
pathogen
andor
bioterror
organ
arriv
new
equip
larg
commun
hospit
laboratori
chemistri
autom
exampl
creat
lot
stress
staff
complet
perform
verif
new
quantit
analyt
system
practic
physician
healthcar
system
depend
equip
perform
well
assay
requir
verif
calibr
linear
analyt
measur
rang
accuraci
precis
appropri
refer
rang
qualiti
control
requir
varieti
poct
main
chemistri
laboratori
method
evalu
see
meet
total
allow
error
goal
set
cap
profici
test
program
nation
glycohemoglobin
standard
program
ngsp
clearli
mani
method
includ
poc
method
perform
well
laboratori
seen
data
cap
profici
survey
new
system
one
good
perform
replac
immunoassay
roch
diagnost
method
siemen
medic
solut
new
method
capillari
electrophoresi
method
sebia
evalu
three
method
roch
immunoassay
report
valu
four
patient
hba
hbsc
screen
random
patient
homozyg
heterozyg
variant
hb
nbaltimor
comigr
capillari
electrophoresi
hb
silver
spring
hb
variant
case
method
quickli
evalu
replac
theimmunoassay
origin
plan
implement
prevent
repeat
profici
test
failur
potenti
discontinu
assay
obsolet
test
test
longer
use
longer
use
tabl
effect
way
evalu
whether
test
becom
obsolet
review
laboratori
util
committe
respons
laboratori
formulari
formulari
concept
come
play
book
pharmaci
therapeut
committe
approv
medic
use
medic
provid
circumst
newer
effect
drug
fda
approv
may
replac
older
less
effect
drug
formulari
laboratori
perfect
obsolet
test
order
medic
provid
reagent
longer
provid
vitro
diagnost
industri
exampl
protein
bound
iodin
pbi
longer
avail
refer
laboratori
test
reagent
longer
manufactur
howev
uptak
obsolet
useless
howev
reagent
still
manufactur
mani
vendor
still
offer
refer
laboratori
util
review
hospit
send
test
volum
ask
refer
laboratori
physician
order
mani
uptak
assay
said
formulari
like
ck
mb
obsolet
test
other
still
order
perform
refer
laboratori
respons
offer
test
physician
order
test
howev
reagent
avail
manufactur
unlik
refer
laboratori
would
develop
laboratori
develop
test
support
obsolesc
workaround
remov
obsolet
test
hospit
laboratori
formulari
usual
involv
use
emr
refer
laboratori
test
order
built
conveni
medic
provid
featur
inactiv
inpati
hospit
laboratori
formulari
develop
leak
flood
abus
origin
local
defin
obsolet
test
univers
accept
elimin
test
list
hospit
manufactur
refer
laboratori
discoveri
ingeni
workaround
occupi
time
medic
provid
habit
accustom
obsolet
test
result
side
util
manag
laboratori
test
larg
commun
hospit
similar
academ
smaller
commun
hospit
numer
factor
influenc
laboratori
util
tabl
outsid
influenc
like
hospit
buy
physician
practic
increas
placement
hospitalist
hospit
consolid
influenc
number
complex
test
menu
need
monitor
util
central
laboratori
refer
laboratori
laboratori
util
committe
laboratori
formulari
stewardship
key
success
begin
numer
excel
suggest
report
success
implement
remedi
review
arrang
gener
toolkit
tool
box
solut
specif
laboratori
section
like
microbiolog
toxicolog
chemistri
transfus
medicin
molecular
diagnost
use
approach
provid
resourc
explor
laboratori
test
util
manag
issu
potenti
resolut
use
method
success
local
geograph
environ
